The Long Interruption
Menopause—once framed narrowly as a reproductive transition—has re-entered mainstream medical, corporate, and policy discourse with unusual velocity. Search trends and ...
The Public Ledger
Over the past several weeks, sustained policy attention has centered on Medicaid eligibility redeterminations, Medicare Advantage payment recalibration, and intensified ...
The Fasting Correction
Intermittent fasting—variously packaged as time-restricted eating, 5:2 cycling, or extended caloric abstention—has occupied a curious space in metabolic discourse: both ...
Care Without Corridors
Home-based medical care and concierge subscription models have moved from niche experimentation to durable growth vectors in U.S. healthcare. Demographic ...
The Muscle Dividend
Healthy aging has emerged as one of the most persistently discussed healthcare themes across clinical conferences, investment forums, and consumer ...
The Price of Staying Covered
Healthcare affordability has reasserted itself as a dominant theme across employer forums, policy briefings, and financial disclosures over the past ...
The Injectable Reordering of American Metabolism
GLP-1 receptor agonists—marketed under brand names such as Ozempic and Wegovy—now reach an estimated one in eight American adults, according ...
The Patient as Data Architecture
Precision medicine—once confined to oncology conference halls and NIH grant language—has moved decisively into mainstream clinical and commercial strategy. Genetic ...
When the Prescription Is Produce
Across health systems, Medicaid waivers, and employer-sponsored benefit designs, “food as medicine” initiatives are moving from demonstration projects to embedded ...
The Delayed Clock
Across the United States and much of the OECD, maternal age continues to rise, with first births increasingly occurring in ...
The Hormone Reckoning
Now it is back—cautiously, strategically, and with far more data than when it was sent away. Interest in hormone replacement ...
Questions to Ask Your Functional Medicine Provider
Remember these important questions to ask your functional medicine provider if you want to make the most out of your ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more